IV Ketamine for TRD: Evidence and Policy in Resource-Limited Settings
A new scoping review assesses clinical outcomes of generic intravenous ketamine for treatment-resistant depression, with implications for public health policy and hospital procurement worldwide.
Repurposing IV Ketamine for Treatment-Resistant Depression
Generic intravenous (IV) racemic ketamine, long used as an anesthetic, is now under serious consideration as a treatment for patients with treatment-resistant depression (TRD) in resource-limited settings. A November 2026 scoping review (OpenAlex W7235324682) systematically maps the clinical efficacy of IV ketamine in TRD, focusing on real-world outcomes that could guide hospital administrators and public health officials. This approach is particularly relevant as patented intranasal esketamine (Spravato) remains prohibitively expensive for many public healthcare systems, while generic ketamine is already stocked in most hospital pharmacies worldwide.
Clinical Outcomes: Response and Remission Rates
Published studies consistently report that IV racemic ketamine produces rapid antidepressant effects in a significant proportion of patients with unipolar or bipolar TRD, with response rates (defined as ≥50% reduction in depression scale scores) ranging from 40% to 70% after one or more infusions. Remission rates, while lower, are still notable, often reaching 20% to 40% in short-term follow-up. The scoping review, using the Joanna Briggs Institute (JBI) methodology and a PubMed-only literature search, extracts these metrics to provide a global overview of efficacy across diverse clinical settings. Notably, the review highlights that most studies are small, single-center trials, and there is considerable heterogeneity in dosing protocols, patient populations, and outcome measures.
- Response rates: 40–70% across studies, typically after 1–6 infusions
- Remission rates: 20–40% in short-term follow-up
- Duration of effect: Antidepressant effects are often transient, with relapse common within weeks without maintenance strategies
One insight not widely discussed in prior literature is the operational advantage: hospitals in low-resource settings already possess the infrastructure and staff training for IV ketamine administration due to its anesthesia use, potentially lowering implementation barriers compared to entirely novel treatments.
Policy and Procurement Implications
Evidence from this review may prompt hospital administrators and policymakers to reconsider the procurement and off-label use of generic IV ketamine for TRD, especially where access to patented esketamine is financially unfeasible. In many countries, the cost differential is dramatic: a single dose of generic IV ketamine can cost less than 5% of the equivalent esketamine nasal spray treatment. This price gap could influence national formularies, insurance reimbursement, and clinical guidelines, particularly in public health systems facing budget constraints.
Furthermore, the review may challenge the market dominance of esketamine by demonstrating that generic racemic ketamine, if used with proper protocols, can deliver comparable short-term outcomes in TRD. However, regulatory pathways for repurposing anesthetic ketamine for psychiatric use remain complex and vary by jurisdiction. Some countries (e.g., Australia, Brazil) have already issued guidance or pilot programs for ketamine in depression, while others restrict its use to research or anesthesia only.
Risks, Unknowns, and Implementation Challenges
While IV ketamine shows promise, significant risks and knowledge gaps remain. Adverse effects—including dissociation, blood pressure elevation, and potential for misuse—require careful patient selection, monitoring, and staff training. The evidence base is still limited by small sample sizes, short follow-up periods, and lack of standardized protocols. Long-term safety, optimal dosing schedules, and comparative effectiveness versus other interventions are not yet established.
Another underappreciated challenge is the administrative burden: in many resource-limited hospitals, psychiatric and anesthesia services are siloed, complicating cross-disciplinary collaboration and patient flow. Without clear institutional pathways, scaling up ketamine infusions for TRD may strain already overburdened systems, even if the drug itself is inexpensive and available.
Looking Forward: Research and Policy Directions
The November 2026 scoping review provides a timely synthesis of global evidence on generic IV ketamine for TRD, equipping public health leaders with data to inform access and procurement decisions. Future research should prioritize large, pragmatic trials in real-world settings, with attention to long-term outcomes, cost-effectiveness, and implementation logistics. Policymakers may need to develop clear clinical protocols, monitoring requirements, and reimbursement models that balance access with patient safety.
As the field evolves, the repurposing of generic IV ketamine could reshape the landscape of depression treatment, particularly in settings where cost and infrastructure are critical constraints. The next phase will depend on robust evidence, thoughtful policy, and multidisciplinary collaboration to ensure safe and equitable access to this emerging intervention.
By Dr. Alex Kim, MD, MPH. How we research: This article was reviewed by Dr. Kim on 2026-11-15, using the primary scoping review (OpenAlex W7235324682) and direct analysis of cited clinical trials and regulatory guidance.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.